Results 161 to 170 of about 4,582,351 (335)

Silent Danger: Coexistence of Late‐Onset External Iliac Artery Pseudoaneurysm and Deep Vein Thrombosis

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Pseudoaneurysm (PA) is a well‐known vascular complication following percutaneous interventions, typically occurring in the early post‐procedural period. However, delayed‐onset PA associated with deep vein thrombosis (DVT) is an uncommon presentation.
Sefa Tatar   +3 more
wiley   +1 more source

Efficacy of Direct Injection in Occlusive Lesion (DIOL) Fashion for Infrapopliteal and Inframalleolar Chronic Total Occlusions

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Endovascular therapy (EVT) for chronic total occlusions (CTOs) in patients with critical limb‐threatening ischemia (CLTI) remains technically challenging, particularly in infrapopliteal lesions. Direct injection in occlusive lesions (DIOL) fashion is a novel adjunctive strategy that utilizes hydraulic contrast injection through a ...
Takuya Haraguchi   +5 more
wiley   +1 more source

Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria. [PDF]

open access: yesPLoS Pathog
Andrew AK   +7 more
europepmc   +1 more source

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang   +9 more
wiley   +1 more source

Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart Disease

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Apixaban is an oral direct inhibitor of factor Xa (FXa) that could be a treatment option for thromboembolism prevention in children with congenital or acquired heart disease (CAHD). Data from SAXOPHONE, a phase II pediatric study, were used to update a previously developed population pharmacokinetics (PPK) model and to assess the covariate effect of ...
Antoinette Ajavon‐Hartmann   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy